Mi SciELO
Servicios Personalizados
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Revista Cubana de Anestesiología y Reanimación
versión On-line ISSN 1726-6718
Resumen
CRUZ GARCIA, Omaní et al. Deep-vein thrombosis and congenital thrombophilia. Rev cuba anestesiol reanim [online]. 2021, vol.20, n.2 Epub 01-Jun-2021. ISSN 1726-6718.
Introduction:
Thrombophilia is a congenital or acquired hemostasis disorder that predisposes to thrombosis development. The commonest congenital thrombophilias are deficiencies of antithrombin III, protein C and protein S, factor V Leiden, prothrombin gene mutation (G20210A), and methylenetetrahydrofolate reductase (MTHFR) mutations.
Objective:
To describe the anesthetic management in a patient with congenital thrombophilia.
Case presentation:
The case is reported of a 19-year-old patient with a family and personal history of deep-vein thrombosis, treatment with double antiplatelet therapy and association of three mutations for congenital thrombophilia (G20210A, A1298C MTHFR and C677T MTHFR), who receives spinal anesthesia for an inguinal herniorrhaphy. Aspirin treatment is maintained. Clopidogrel is suspended seven days before surgery. During this time, fraxiparin is administered subcutaneously in 0.6-mL units daily, up to twelve hours before surgery. Elastic stockings are used, early ambulation is allowed, and clopidogrel is restarted 24 hours after surgery, with satisfactory evolution.
Conclusions:
Thromboprophylaxis in patients with congenital thrombophilia is mandatory, a reason why the use of low-molecular-weight heparin, together with the rest of the prevention measures against deep-vein thrombosis, is decisive.
Palabras clave : deep-vein thrombosis; congenital thrombophilia; spinal anesthesia; thromboprophylaxis.